Rationaler for behandling med januskinase ½-hæmning af svært syge patienter med COVID-19-pneumoni

Hans Carl Hasselbalch; Anne Poulsen; Vibe Skov; Lasse Kjær; Claus Henrik Nielsen; Troesl Dirch Poulsen

Rationaler for behandling med januskinase ½-hæmning af svært syge patienter med COVID-19-pneumoni

Translated title of the contribution: Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia

Hans Carl Hasselbalch, Anne Poulsen, Vibe Skov, Lasse Kjær, Claus Henrik Nielsen, Troesl Dirch Poulsen

Department for Rheumatology and Spine Diseases

Abstract

Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.

Translated title of the contribution	Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	182
Issue number	25
ISSN	0041-5782
Publication status	Published - 15 Jun 2020

Cite this

@article{720dfdd513b24ed5964c61e6bfe566a4,

title = "Rationaler for behandling med januskinase ½-h{\ae}mning af sv{\ae}rt syge patienter med COVID-19-pneumoni",

abstract = "Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.",

keywords = "Betacoronavirus, COVID-19, Coronavirus Infections/drug therapy, Humans, Janus Kinase Inhibitors/therapeutic use, Lymphohistiocytosis, Hemophagocytic/drug therapy, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2",

author = "Hasselbalch, {Hans Carl} and Anne Poulsen and Vibe Skov and Lasse Kj{\ae}r and Nielsen, {Claus Henrik} and Poulsen, {Troesl Dirch}",

year = "2020",

month = jun,

day = "15",

language = "Dansk",

volume = "182",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "25",

}

TY - JOUR

T1 - Rationaler for behandling med januskinase ½-hæmning af svært syge patienter med COVID-19-pneumoni

AU - Hasselbalch, Hans Carl

AU - Poulsen, Anne

AU - Skov, Vibe

AU - Kjær, Lasse

AU - Nielsen, Claus Henrik

AU - Poulsen, Troesl Dirch

PY - 2020/6/15

Y1 - 2020/6/15

N2 - Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.

AB - Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.

KW - Betacoronavirus

KW - COVID-19

KW - Coronavirus Infections/drug therapy

KW - Humans

KW - Janus Kinase Inhibitors/therapeutic use

KW - Lymphohistiocytosis, Hemophagocytic/drug therapy

KW - Pandemics

KW - Pneumonia, Viral/drug therapy

KW - SARS-CoV-2

M3 - Review

C2 - 32584762

SN - 0041-5782

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 25

ER -

Rationaler for behandling med januskinase ½-hæmning af svært syge patienter med COVID-19-pneumoni

Abstract

Fingerprint

Cite this